Gaidaa M Dogheim (Gaidaa Dogheim)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Atrial Fibrillation

Pseudomonas Aeruginosa

Top Venues

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Drug development research

European journal of clinical pharmacology

Inflammopharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Gaidaa M Dogheim, Mohamed T Amralla, Rehab H Werida
The clinical significance of neopterin and NT-pro BNP in chronic heart failure: a systematic review. Acta cardiologica (2024)
Gaidaa M Dogheim, Sampath Chinnam, Mohamed T Amralla
Lipid Nanoparticles as a Platform for miRNA and siRNA Delivery in Hepatocellular Carcinoma. Current drug delivery (2024)
Gaidaa M Dogheim, Mohamed T Amralla
Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC). Drug development research (2023)
Gaidaa M Dogheim, Rehab H Werida
Drug Utilization Evaluation Study of Ciprofloxacin Use and Adverse Events Occurrence: Role of Community Pharmacists. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 40 (1) (2023)
Gaidaa M Dogheim, Rehab H Werida
Drug Utilization Evaluation Study of Ciprofloxacin Use and Adverse Events Occurrence: Role of Community Pharmacists. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 40 (1) (2023)
Gaidaa M Dogheim, Ibtsam Khairat, Gamal A Omran, Sahar M El-Haggar, Ahmed M El Amrawy, Rehab H Werida
Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients. European journal of clinical pharmacology 78 (6) (2022)
Gaidaa M Dogheim, Mohamed T Amralla, Rehab H Werida
Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level. Inflammopharmacology 30 (5) (2022)